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MR‐linac is the best modality for lung SBRT
1 | INTRODUCTION
The introduction of MR‐linac hybrid modality started a new era in
image guidance for radiotherapy. It provides superior soft tissue con-
trast compared to conventional x‐ray imaging, and offers the ability
to track and gate treatment delivery, yet challenges and limitations
remain in various aspects.1 Our previous Parallel Opposed issues dis-
cussed the additional physicist qualification and residency require-
ments for the use of MRI in radiotherapy settings.2,3 Herein, we
continued our discussion on the clinical use of MR‐linac and its
potential improvement in treatment efficacy for lung stereotactic
body radiotherapy (SBRT). Dr. Andrew Godley believes that “MR‐li-
nac is the best modality for lung SBRT,” while Dr. Dandan Zheng
explained her doubts and concerns.
Dr. Andrew Godley received his Ph.D. in High Energy Physics
from the University of Sydney in 2001. Dr Godley continued in par-
ticle physics at the University of South Carolina and Fermilab, until
2007 when he trained in medical physics at the Medical College of
Wisconsin. Dr. Godley spent 7 years as a staff physicist at the
Cleveland Clinic before joining the Miami Cancer Institute in 2018
to help develop their MR‐linac and SBRT programs.
Dr. Dandan Zheng received her Ph.D. in Applied Science from
the University of California Davis in 2007. After conducting a post-
doctoral training in Radiation Oncology at Virginia Commonwealth
University, she joined the department as an assistant professor in
2009. In 2012 Dr. Zheng moved to University of Nebraska Medical
Center where she is currently an associate professor and the medical
physics residency program director. Dr. Zheng is an avid peer
reviewer/associate editor for many journals, and her research inter-
ests include image guidance, radiomics and machine learning, stereo-
tactic RT, dose algorithms, and motion management.
2 | OPENING STATEMENT
2.A | Dr. Andrew Godley
One vision of future radiotherapy is for patients to arrive for
treatment, lie down on the couch, and the treatment system to
automatically locate and irradiate their tumor, regardless of its
position or motion, sparing all but the surrounding few millimeters
of normal tissue. The hybrid technology of MR‐guided linear accel-
erator is today's embodiment of that vision. It provides three main
advantages to patients: monitoring the actual tumor location
during treatment delivery, comfort, and accuracy. These advan-
tages would benefit any patient undergoing radiotherapy, but pro-
vide specific gains for lung SBRT patients. Clinical trials have
shown lung SBRT already achieves 98% tumor control, however
there is still a 17% risk of grade 3–4 toxicity4 and it requires
oppressive patient immobilization. The fast‐growing number of
patients eligible for lung SBRT further presses the need for tech-
nological improvement. The MR‐linac tracking and accuracy reduce
the volume of normal lung and chest wall irradiated, decreasing
toxicity, and obviating the need for immobilization.
MR‐linac provides the best targeting of any system available as it
directly images the tumor throughout treatment delivery. The rea-
sons are four‐fold: First, 2D cine‐MRI based tumor tracking enables
gating directly on the tumor position relative to the planned position.
This cine imaging incurs no additional radiation exposure. Although
some conventional systems acquire planar imaging during treatment,
the radiation dose over a large area would be excessive to achieve
the continuous monitoring of the MR‐linac. Second, while using
external surrogates facilitates continuous monitoring, these surro-
gates require at least an additional 1 mm margin to ensure correla-
tion with the tumor.5 Third, the precise gating window of the MR‐
linac provided by its continuous tumor tracking limits or eradicates
multileaf collimator (MLC) interplay issues, which was reported to
affect delivery accuracy of other modalities6 and thus reduce target
coverage.7 Lastly, the tumor based gating eliminates the need to
define an internal target volume (ITV), which is conventionally used
to ensure tumor coverage during the breathing cycle, but increases
the volume of normal lung irradiated. Further, traditional ITVs are
just a snapshot of tumor motion observed over tens of seconds in a
4D CT. When compared to a treatment length cine‐MRI based ITV,
the four‐dimensional computed tomography (4D CT) based ITV typi-
cally captures only 45%–90% of the required volume,8 leading to
potential under dosing. The MR‐linac continuous tracking accounts
for the breathing motion including large excursions of the tumor, so
that this motion does not have to be forcibly limited.
With the above‐mentioned target monitoring and tracking, immo-
bilization for MR‐linacs does not then feature compression or breath
control, leading to higher patient comfort during treatment. Due to
the continuous imaging of the tumor, the patient can be coached by
the therapists during treatment, or even see and respond to their
own cine‐MRI, in order to achieve optimal breath holds. By consis-
tently placing the tumor in the gating window, the gating duty cycle
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is increased and treatment times reduced. Video feedback for
breath‐hold delivery has been positively viewed by patients treated
on the MR‐linac.9 Commonly no immobilization is necessary, with
the patient arranged comfortably on the couch. No implanted fidu-
cials are required either, making for a safer and noninvasive treat-
ment. This increased patient comfort is achieved without limiting the
accuracy of the MR‐linac.
The MR‐linac allows several other major improvements in terms of
accuracy in planning and treatment. The treatment planning algorithm
used for MR‐linac planning has always been based on Monte Carlo
simulation, which provides a more accurate dose estimation than used
by many conventional SBRT planning systems.10 In addition, the pre-
treatment volumetric MR imaging can be acquired in 17 s, not only
does this make for an easier breath hold than for current cone‐beam
CTs, but it also reduces averaging of the tumor due to motion from
repeated or longer breath holds. This leads to more accurate alignment
of the patient in the MR‐linac. Furthermore, the minimum 4 Hz rate of
cine‐MRI allows for the capture of cardiac derived tumor motion for
central lesions, something that would be missed by all other means of
intrafractional lung imaging, and would lead to higher toxicities or
under coverage of the tumor. This fast rate of tumor imaging can
enable MLC tracking,11 which currently relies on implanted fiducials
and portal images that are often blocked by the MLC. Finally, an MR‐li-
nac can provide diagnostic sequences daily, such as dynamic contrast
enhanced and diffusion weighted, to observe treatment response.12,13
Observed changes in tumor volume coupled with tumor response data
can inform dose adaption, to provide the optimal curative dose.
As MR‐linacs become more prevalent, these advantages will be
borne out in improved outcomes for our lung SBRT patients. Any
disadvantages of MR‐linacs will be eroded as the technology
advances. While conventional linacs have achieved excellent lung
tumor control rates, their lack of tumor imaging during treatment
has left us irradiating unnecessarily large volumes of normal lung tis-
sue and chest wall. Thankfully we now have the technology to allevi-
ate this and continue the success of lung SBRT with the MR‐linac.
2.B | Dr. Dandan Zheng
Since its clinical introduction, the MR‐linac has quite often attracted
the spotlight as the state‐of‐the‐art treatment modality in the era of
image‐guided adaptive radiotherapy. MRI‐guidance may provide the
much needed breakthrough for disease sites such as pancreas, where
other radiotherapy treatment modalities lack efficacy due to dose‐
limiting normal tissue toxicity, poor on‐board x‐ray contrast, and
weak internal motion‐external surrogate correlation, etc. When it
comes to the titled statement for lung SBRT, however, I cannot
agree that the MR‐linac represents the best modality for reasons
elaborated below.
2.B.1 | Technical limitations of the linac component
Integrating MRI and linac poses tremendous technical challenges on
both systems.14–18 While the integration has finally been made
feasible after decades of R&Ds, the linac component in an MR‐linac
is still not up to the highest standard of modern linacs. The essential
technologies pertaining to treatment time reduction for lung SBRT,
such as volumetric modulated arc therapy (VMAT) and high dose
rates (up to 2400 MU/min),19,20 are not available on the MR‐linac.
Currently, the MR‐linac is only capable of step‐and‐shoot, low dose
rate (450 MU/min for Elekta Unity or 600 MU/min for ViewRay
MRIdian), low gantry speed, and low MLC speed, all of which sub-
stantially lengthen the treatment duration. This prolonged treatment
time poses contraindication for patients who cannot tolerate due to
back pain or poor performance status, and increases treatment varia-
tions and motion uncertainty. In addition, the MR‐linac has a limited
lateral range of isocenter and forces off‐axis geometry for those
tumors located outside the range. This can potentially lead to exces-
sive monitor units and hence high integral dose to normal tissue.21
The couch correction range is also limited with no option of couch
rotation and, in some models, lateral translation. Furthermore, the
electron return effect is much more pronounced in lung and can lead
to considerable dose distortion at tissue‐air interfaces. Some early
studies have shown increased dose in lung and skin, as well as com-
promises to the accuracy of both patient plan and QA dosime-
try.11,22,23
2.B.2 | Technical limitations of the MR component
The most desirable features to those early adopters might be the
real‐time internal imaging capability with an MR scanner. However,
cautions should be taken as they are not standard diagnostic MR
scanners either. First, the MR‐linac often uses lower magnetic field
strengths than diagnostic MRIs (e.g., ViewRay MRIdian uses a 0.35 T
scanner), therefore rendering compromised MR image quality. Sec-
ond, the limited real‐time tracking range excludes those cases with
very peripheral lesions. Third, real‐time target monitoring is based on
2D MR cine images, therefore omitting the volumetric or the third‐
dimension motion information. Fourth, the MR sequences typically
used for lung are prone to irregular breathing artifacts and banding
artifacts.24 Fifth, in the desirable adaptive radiotherapy application,
MRI cannot provide the CT‐number information for heterogeneity
correction which is especially important for lung SBRT dose calcula-
tion. Any method to address this fundamental limitation introduces
additional uncertainties which are more pronounced for lung
because lung and bone feature little MR signal.25 Last but not least,
tissue heterogeneity in lung can induce pronounced geometric dis-
tortions in MR images due to local susceptibility differences, and
these errors are in addition to other MR distortions such as those
due to main magnetic field and gradient field nonlinearity.26
2.B.3 | Incompatible patient populations
For the patient population with any contraindication against MRI,
the MR‐linac is not an option. These include patients with claustro-
phobia and those with ferromagnetic implants such as prostheses,
cardiac pacemakers and defibrillators, artificial heart valves, and
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cochlea implants. In addition, due to the bore size limitation, the
MR‐linac also excludes large patients and prevents the use of many
immobilization devices and body positions.
2.B.4 | Alternative modalities
Currently, there are many successful alternative modalities and tech-
nologies for lung SBRT that the MR‐linac cannot rival. As mentioned
previously, standard linacs are capable of delivering highly conformal
lung SBRT plans at very high speeds with VMAT and high dose
rates.19 Less uncertainty and higher accuracy are further ensured
with the combinations of various imaging options (such as cone
beam CT (CBCT), 4D CBCT, fluoroscopy, and triggered MV/kV imag-
ing) as well as gating or tracking mechanisms (such as external fidu-
cial‐ or surface‐based optical tracking and internal fiducial‐based
radiofrequency tracking). Tumor motion can also be mitigated by
breath‐holding techniques such as active breathing control, compres-
sion techniques, and audio‐visual coaching with feedback. In addi-
tion, target dosimetry can be optimized with noncoplanar geometries
and 6‐degree‐of‐freedom couch corrections. Furthermore, systems
such as CyberKnifeTM have demonstrated extensive success using
real time tumor tracking with combined internal and external track-
ing.27
2.B.5 | Health economics
MR‐linacs are expensive at a price point 2–4 times of standard linacs
and therefore remain questionable as a cost‐effective modality for
value‐based health care. Its cost could be more justified in diseases
such as pancreatic cancer where the current treatment efficacy is
poor and x‐ray based imaging does not provide sufficient contrast.
Whereas the excess cost may not be justified for lung SBRT where
the standard treatment modalities are much more cost‐effective and
highly successful with >90% local control rates and low toxicity to
normal tissues, along with adequate image‐guidance and track-
ing.27,28
In conclusion, MR‐linac is clearly not a viable lung SBRT treat-
ment modality for a large population of patients with contraindica-
tions. For the other patients, it is still not the best modality based
on the arguments above, as the alternative modalities provide more
advanced dosimetry and delivery efficiency, more robust and versa-
tile image guidance and motion management approaches, clear cost‐
effectiveness, and well‐documented clinical success.
3 | REBUTTAL
3.A | Dr. Andrew Godley
I would like to thank my colleague and friend Dr. Zheng for elo-
quently sharing her concerns with MR‐Linac lung SBRT. I am happy
to now assuage those concerns. The first of which is treatment time.
While treatment delivery is the one advantage of conventional linacs,
due to the extra time required for patient setup, immobilization,
image guided radiotherapy (IGRT) (especially if multiple imaging
modalities are used), and gating a conventional linac SBRT lung
treatment still ends up in the same 45 min timeslot as our MR‐linac
SBRT. Technical limitations are not solely the bugbear of MR‐linacs.
Conventional linacs have limited gantry and couch angles for lateral
tumors, and Cyberknife is limited in utility for posterior tumors.
While there are increased MU for off‐axis MR‐linac treatments, the
double stack MLC means there is no increase in leakage radiation.
The article cited21 in fact finds no other issues with off‐axis treat-
ment. In terms of aligning the patient after imaging, commercial MR‐
linacs either shift the couch or shift the MLC and rotational correc-
tions are not dosimetrically important for lung SBRT.29 Electron
return effect is accounted for in the Monte Carlo dose planning and
there is only an increase for skin in standard fractionation, not
SBRT.22 The article however confirms lung dose is lowered due to
reduced margins of lung SBRT on the MR‐linac.
Perplexingly, Dr. Zheng suggests imaging as a weakness of MR‐li-
nac by comparing it to diagnostic MR, rather than the low quality
CBCT or planar kV conventional linacs rely on. MR‐linacs achieve
spatial accuracy of 1–2 mm in a 35 cm diameter sphere.30 Their
70 cm bore allows for lateral patient shifts in order to ensure all tar-
gets can be within this spatially accurate region and will track well.
Breath holds are used to ensure the 3D MR image is not affected by
motion. While adaptive lung SBRT is not as common as other sites,
it can certainly be accomplished on the MR‐linac31 and CBCTs also
lack correct electron density. MRI has been in use since the 1970s,
as such the majority of modern medical implants have been manu-
factured to be MR safe including all joint implants and recent
implantable cardiac devices. With the low field strength of MR‐linacs,
many more are compatible. Patients undergoing any radiotherapy
can have anxiety, and are medicated as needed.
My opening statement addressed the advantages of the MR‐linac
over current modalities. In particular, it mentioned the extra radiation
required for CBCT (4D!) and fluoroscopy. The only modality Dr.
Zheng discussed that could provide continuous tumor monitoring is
radiofrequency tracking, but this requires an invasive procedure to
implant the markers. Cyberknife is limited in size and position of
tumors for its marker‐less tracking.32 All the other techniques are
only surrogates for the tumor position. Lastly Dr. Zheng mentions
cost. To the patient there is no difference in cost. The MR‐linac pur-
chase cost is actually only 1–2 times a conventional linac, depending
on how many extras like 4D CBCT, radiofrequency tracking, 6DoF
couch, or gating you buy in an attempt to reach the tracking ability
of the MR‐linac.
In summary, the only compelling advantage of conventional
linacs is their delivery speed, but without continuous tumor tracking,
this just allows you to miss the target quicker. Hence I maintain that
MR‐linac is the best modality for lung SBRT.
3.B | Dr. Dandan Zheng
I, too, share the vision of Dr. Godley's on the ideal radiotherapy treat-
ment. But today's MR‐linac is far from the embodiment of that vision.
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More importantly, while the MR‐linac should be further advanced as a
frontrunner modality toward that vision for diseases like pancreatic
cancer, it is not the case for lung SBRT. For pancreas, current radio-
therapy provides relatively poor efficacy with organ toxicity partly due
to low soft‐tissue imaging contrast, while MRI may offer the important
soft‐tissue contrast resolution that is superior to the competing x‐ray
technologies. Whereas for lung, contrast is not as challenging, and cur-
rent SBRT can already achieve 98% tumor control as cited by Dr. God-
ley.4 As discussed above and will be stressed again below, numerous
existing technical issues in MR‐linacs make it far from being the ulti-
mate solution toward that vision. But even hypothetically assuming all
issues would have been perfectly resolved someday, arguing for the
MR‐linac as the best modality for lung SBRT would still be like arguing
for proton therapy for prostate: Are there enough clinically meaningful
gains to justify the higher cost?
Let's revisit MR‐linacs' three main advantages laid out by Dr.
Godley.
3.B.1 | Comfort
With VMAT, high dose rates and fast collimators, lung SBRT treat-
ment delivery time can be dramatically shortened to 2–3 min on
standard linacs. Due to the magnetic field, MR‐linacs pose technical
limitations that lengthen the treatment by several folds. On top of
that, MR‐gating can prolong treatment delivery even more. For a
treatment that currently takes minutes on standard linacs and may
someday take seconds with FLASH‐RT,33 how would its hour‐long
gated counterpart on MR‐linacs increase patient comfort?
3.B.2 | Accuracy
In the opening statement Dr. Godley described, “MR‐linac provides
the best targeting of any system available as it directly images the
tumor throughout treatment delivery.” This statement is misleading
because it assumes a huge leap of faith. Being able to “image” the
tumor real time is far from being able to “target” it real time. TG76
summarizes respiratory motion management in four main approaches:
(a) motion‐encompassing, that is, ITV; (b) respiratory gating, (c) volun-
tary or involuntary breath hold (including compression); and (d) real‐
time tumor‐tracking.34 Dr. Godley described MR‐tracking as real‐time
tumor‐tracking, the most desirable approach from the above list,
where it “continuously accounts for the breathing motion including
large excursions of the tumor.” But this mode is currently unavailable
on MR‐linacs as only the first of four necessary conditions is provided
for real‐time tumor‐tracking that is, identifying the tumor position in
real time. MR‐linacs offer no solution for the other three critical
requirements: motion prediction to address latency, repositioning of
the beam, and dose adaptation for changing anatomy. With the pres-
ence of the magnetic field, repositioning of the beam will be particu-
larly challenging. In contrast, CyberKnifeTM has already developed a
working real‐time tracking solution using its robotic linac and Syn-
chronyTM system and had years of documented clinical success.27
Meanwhile, standard linacs also have developed solutions such as
MLC‐tracking and couch‐tracking,35,36 but these solutions would be
difficult to adopt on MR‐linacs due to the interfering magnetic field.
The so‐called “MR‐tracking” is not really “tracking” but gating, which
substantially lengthens the treatment duration and has fallen out of
fashion for lung SBRT because of it. In fact, the MR‐gating may actu-
ally be managing the extra motion uncertainty created by the length-
ened treatment but does not necessarily improve the overall accuracy.
The much larger (compared with the conventional ITV) MR‐ITV cre-
ated with treatment‐length cine MRIs that Dr. Godley described earlier
might serve as a proof to this.8 Since the current high tumor control
rate argues against the tumor underdosing using the conventional ITV
that Dr. Godley cautioned about, I would offer another more likely rea-
son for the larger MRI‐ITV volumes: an effect of the increased motion
uncertainty due to the much longer “treatment length”!
3.B.3 | Tumor monitoring
Although incapable of real‐time tumor targeting, the expensive MR‐
linac does provide the desirable real‐time tumor monitoring. How-
ever, for lungs, such monitoring capability is not unique to MRI due
to high x‐ray imaging contrast and minimally invasive fiducial implan-
tation procedures. Continuous x‐ray monitoring based on tumors or
fiducials has long been established and achieved high precision for
lung. Significantly shortened treatment delivery and SBRT hypo‐frac-
tionation have further alleviated concerns about additional radiation
exposure. Meanwhile, exposure‐free radiofrequency tracking has
been FDA‐approved for lung and can be integrated with real‐time
MLC‐tracking.35 In addition to these mature technologies, the feasi-
bility of other real‐time lung‐tumor monitoring has also been demon-
strated with radiation‐dose‐free Compton‐scatter imaging using the
therapy beam37 and with PET emission guidance.38
In summary, MR‐linacs should be better used where they are
needed. For lung SBRT, competing technologies are highly success-
ful, and offer higher cost‐effectiveness and better solutions.
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